Atlas funds tied to Kymera (KYMR) director sell 81,866 shares under plan

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. director-associated venture funds reported open-market sales of a combined 81,866 shares of common stock at a weighted average price of about $90.13 per share. Atlas Venture Fund X, L.P. sold 71,814 shares and Atlas Venture Opportunity Fund I, L.P. sold 10,052 shares on March 2, 2026.

These trades were executed under a Rule 10b5-1 trading plan adopted on December 11, 2025. Bruce Booth is a member of the general partner entities of these funds and disclaims Section 16 beneficial ownership of the funds’ holdings except to the extent of his pecuniary interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Booth Bruce

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

200 ARSENAL YARDS BLVD., SUITE 230

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		S(1)		71,814	D	$90.13(2)	3,902,667	I	See footnote(3)
Common Stock	03/02/2026		S(1)		10,052	D	$90.13(2)	675,341	I	See footnote(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.05 to $90.441 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the range set forth in this footnote.

3. These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extend of his pecuniary interest therein, if any.

4. The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any.

	/s/ Ommer Chohan, Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Kymera Therapeutics (KYMR) disclose?

Kymera Therapeutics disclosed that venture funds associated with director Bruce Booth sold 81,866 shares of common stock in open-market transactions at a weighted average price near $90.13 per share, executed on March 2, 2026 under a prearranged trading plan.

Who actually sold Kymera Therapeutics (KYMR) shares in this Form 4?

The shares were sold by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P.. Bruce Booth is a member of their general partner entities and disclaims Section 16 beneficial ownership except for any pecuniary interest he may have.

How many Kymera (KYMR) shares did each Atlas fund sell?

Atlas Venture Fund X, L.P. sold 71,814 shares of Kymera common stock, while Atlas Venture Opportunity Fund I, L.P. sold 10,052 shares. Both sales occurred on March 2, 2026 in open-market transactions at prices around $90 per share.

At what prices were the Kymera (KYMR) insider sales executed?

The reported price per share is a weighted average of $90.13. The filing notes actual trades were executed in multiple transactions at prices ranging from $90.05 to $90.441 per share, all occurring on March 2, 2026.

Was the Kymera (KYMR) insider sale under a Rule 10b5-1 plan?

Yes. The filing states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2025. Such plans allow pre-scheduled trades, helping insiders diversify holdings while following securities regulations and avoiding ad hoc timing decisions.

How many Kymera (KYMR) shares do the Atlas funds report after the sale?

After the transactions, Atlas Venture Fund X, L.P. reports holding 3,902,667 shares, and Atlas Venture Opportunity Fund I, L.P. reports 675,341 shares. Bruce Booth disclaims beneficial ownership of these positions except for any pecuniary interest he may have.